Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Sepsis
Interventions
DEVICE

Isomark Canary™

Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.

Trial Locations (6)

32209

University of Florida, Jacksonville

32608

University of Florida Health, Gainesville

43210

The Ohio State University, Columbus

53706

University of Wisconsin - Madison, Madison

53711

Isomark, LLC, Madison

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

University of Florida

OTHER

collaborator

Ohio State University

OTHER

collaborator

Washington University School of Medicine

OTHER

collaborator

University of Colorado, Denver

OTHER

lead

Isomark, LLC

INDUSTRY

NCT02327130 - Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients | Biotech Hunter | Biotech Hunter